We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
- Authors
Lai, Ying-Chieh; Chang, Wen-Cheng; Chen, Chun-Bing; Wang, Chi-Liang; Lin, Yu-Fen; Ho, Ming-Mo; Cheng, Chi-Yuan; Huang, Pei-Wei; Hsu, Chao-Wei; Lin, Gigin
- Abstract
<bold>Background: </bold>Pseudoprogression is difficult to diagnose in patients undergoing immunotherapy. Subjective response assessment is still common in clinical practice.<bold>Purpose: </bold>To evaluate the differences between response evaluation criteria in solid tumors version 1.1 (RECIST 1.1), immune-related response criteria (irRC), and modified RECIST 1.1 for immunotherapy (iRECIST) through semi-automatic software, and to compare iRECIST-based response evaluation with subjective assessment.<bold>Material and Methods: </bold>The best overall response of each patient based on RECIST 1.1, irRC, and iRECIST was determined on CT scans through semi-automatic software and the differences between the criteria were evaluated. Criteria-based response evaluation through semi-automatic software was compared with subjective assessment on radiology report by correlating the best overall response to overall survival.<bold>Results: </bold>A total of 21 patients were included (five patients with melanoma, 12 patients with non-small-cell lung cancer, and four patients with hepatocellular carcinoma). Two patients with progressive disease by RECIST 1.1 but non-progressive disease by irRC and iRECIST eventually experienced tumor response and had favorable outcomes, indicating pseudoprogression. The survival difference between patients with non-progressive disease and progressive disease was better stratified through iRECIST-based response evaluation (P = 0.078) than that through subjective assessment (P = 0.501).<bold>Conclusion: </bold>Pseudoprogression in immunotherapy may be captured through semi-automatic software utilizing irRC or iRECIST criteria. iRECIST-based response evaluation may provide a better survival stratification compared with subjective assessment.
- Subjects
NON-small-cell lung carcinoma; IMMUNOTHERAPY; COMPUTER software
- Publication
Acta Radiologica, 2020, Vol 61, Issue 7, p983
- ISSN
0284-1851
- Publication type
journal article
- DOI
10.1177/0284185119887588